ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors Vote may lead to rollback of some indications held by BMS and Merck

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Clinical, real-world data reaffirming the long-term effectiveness of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and Gardasil (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases will be presented at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, March 18-21.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Combination treatment may dramatically improve survival in brain cancer

A study suggests that laser interstitial thermal therapy using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda) for patients with recurrent high grade astrocytoma, including glioblastoma.

March 06, 2026

Vol.52 No.09

Drugs & Targets

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk of event-free survival events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.

March 06, 2026

Vol.52 No.09

Cancer Policy

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA has granted sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2 directed antibody-drug conjugate, a priority voucher via the agency’s Commissioner’s National Priority Voucher (CNPV) Pilot Program.

January 09, 2026

Vol.52 No.1

By Claire Marie Porter

Clinical Roundup

ASTRO publishes first guideline focused on radiation therapy for gastric cancer

A clinical guideline from the American Society for Radiation Oncology is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration with systemic therapy, and treatment delivery.

December 05, 2025

Vol.51 No.44

Drugs & Targets

FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer

FDA approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. These approvals represent the first PD-1 inhibitor plus ADC regimens for this patient population.

December 05, 2025

Vol.51 No.44

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors

Vote may lead to rollback of some indications held by BMS and Merck

YOU MAY BE INTERESTED IN

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Combination treatment may dramatically improve survival in brain cancer

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

ASTRO publishes first guideline focused on radiation therapy for gastric cancer

FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer

Renew today!

Subscriber content

Never miss an issue!

Login